Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (4)
  • Open Access

    ARTICLE

    CSRNP1 Promotes Apoptosis and Mitochondrial Dysfunction via ROS-Mediated JNK/p38 MAPK Pathway Activation in Hepatocellular Carcinoma

    Huihui Shi1,#, Lei Chen2,#, Juan Huang3,#, Xuejing Lin2, Lei Huang4, Min Tang4, Kai Lu5,*, Wenchao Wang4,*, Maoling Zhu1,§,*

    Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.068737 - 30 December 2025

    Abstract Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. This study aimed to identify key genes involved in HCC development and elucidate their molecular mechanisms, with a particular focus on mitochondrial function and apoptosis. Methods: Differential expression analyses were performed across three datasets—The Cancer Genome Atlas (TCGA)-Liver Hepatocellular Carcinoma (LIHC), GSE36076, and GSE95698—to identify overlapping differentially expressed genes (DEGs). A prognostic risk model was then constructed. Cysteine/serine-rich nuclear protein 1 (CSRNP1) expression levels in HCC cell lines were assessed via western blot (WB) and quantitative reverse transcription polymerase chain reaction (qRT-PCR).… More > Graphic Abstract

    <i>CSRNP1</i> Promotes Apoptosis and Mitochondrial Dysfunction via ROS-Mediated JNK/p38 MAPK Pathway Activation in Hepatocellular Carcinoma

  • Open Access

    ARTICLE

    BMP-2 Inhibits the Inflammatory Response and Promotes Bone Formation in Rats with Femoral Fracture by Activating the AMPK Signaling Pathway

    Yong Huang1, Xiandeng Li1, Qingling Jing1, Qin Zhang1, Chungui Huang2,*

    BIOCELL, Vol.49, No.11, pp. 2195-2216, 2025, DOI:10.32604/biocell.2025.072716 - 24 November 2025

    Abstract Objective: Mesenchymal stem cells (MSCs) are important cells in bone tissue engineering. Bone morphogenetic protein-2 (BMP-2) effectively treats bone defects and nonunion. The purpose of this study is to investigate whether BMP-2 promotes bone formation and femoral fracture healing by inhibiting inflammation and promoting osteogenic differentiation of MSCs, in order to provide an experimental basis for developing more efficient fracture treatment strategies. Methods: Bone marrow-derived MSCs (BMSCs) were isolated from rats and treated with OE-BMP-2, the 5-adenosine monophosphate-activated protein kinase (AMPK) signal agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), and the inhibitor Compound C. Osteogenic differentiation was evaluated through… More >

  • Open Access

    REVIEW

    Dysregulated PI3K/AKT signaling in oral squamous cell carcinoma: The tumor microenvironment and epigenetic modifiers as key drivers

    VINOTHKUMAR VEERASAMY1, VEERAVARMAL VEERAN2, SIDDAVARAM NAGINI1,3,*

    Oncology Research, Vol.33, No.8, pp. 1835-1860, 2025, DOI:10.32604/or.2025.064010 - 18 July 2025

    Abstract The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway is one of the most frequently dysregulated signaling networks in oral squamous cell carcinoma (OSCC). Although the tumor microenvironment (TME) and epigenetic modifiers are recognized to play a pivotal role in aberrant activation of the PI3K/AKT pathway in OSCC, the available evidence is fragmentary and a comprehensive analysis is warranted. This review evaluates the intricate mechanisms by which various components of the TME facilitate proliferation, apoptosis evasion, invasion, migration, angiogenesis, metastasis, as well as therapy resistance in OSCC through activation of PI3K/AKT signalling. The review has also More >

  • Open Access

    REVIEW

    A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases

    NILAM BHUSARE, MAUSHMI KUMAR*

    Oncology Research, Vol.32, No.5, pp. 849-875, 2024, DOI:10.32604/or.2024.047042 - 23 April 2024

    Abstract Glioblastoma, the most aggressive form of brain tumor, poses significant challenges in terms of treatment success and patient survival. Current treatment modalities for glioblastoma include radiation therapy, surgical intervention, and chemotherapy. Unfortunately, the median survival rate remains dishearteningly low at 12–15 months. One of the major obstacles in treating glioblastoma is the recurrence of tumors, making chemotherapy the primary approach for secondary glioma patients. However, the efficacy of drugs is hampered by the presence of the blood-brain barrier and multidrug resistance mechanisms. Consequently, considerable research efforts have been directed toward understanding the underlying signaling pathways… More > Graphic Abstract

    A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases

Displaying 1-10 on page 1 of 4. Per Page